Search

Urinary Biomarkers of Renal Mitochondrial Dysfunction

Company: SCHNELLGEN, INC. Agency/Program/Year/Phase: HHS / STTR / 2013 / 1
Abstract: DESCRIPTION (provided by applicant): The long-term goal of this project is to identify and validate biomarkers of mitochondrial dysfunction due to environmental stressors. Diverse acute insults from surgery, trauma, ischemia/reperfusion (I/R) and drug andenvironmental chemical toxicity lead to… more

Non-invasive method to evaluate the quality of human oocytes and embryos

Company: RENOVA LIFE, INC. Agency/Program/Year/Phase: HHS / STTR / 2013 / 1
Abstract: DESCRIPTION (provided by applicant): Project Summary We propose to develop a non-invasive method to predict mammalian oocyte quality by analyzing the surrounding cumulus cells' gene expression patterns (cGEP). The result of the cGEP assay---a cGEP score---can be used to predict embryo quality… more

Mini ECMO Life Support System

Company: MC3, INC. Agency/Program/Year/Phase: HHS / STTR / 2013 / 1
Abstract: DESCRIPTION (provided by applicant): For twenty years prolonged extracorporeal life support (ECLS ECMO) has been standard treatment for infants with severe heart or lung failure unresponsive to other treatment. The healthy survival rate in over 30,000 cases ranges from 40% in cardiac arrest to 95%… more

Body Worn EMG Controlling of Assistive Robotic Arm for Stroke Rehabilitation

Company: ADVANCED MEDICAL ELECTRONICS CORPORATION Agency/Program/Year/Phase: HHS / STTR / 2013 / 1
Abstract: DESCRIPTION (provided by applicant): Stroke is the leading cause of adult disability and the third leading cause of death in the United States. Approximately 15 million people in the world, and more than 700,000 people in the United States, experience a stroke each year. Following a hemispheric… more

Tumor-toxic CD47 mAb therapy for leukemia: a proof of concept study

Company: VASCULOX, INC. Agency/Program/Year/Phase: HHS / STTR / 2013 / 1
Abstract: DESCRIPTION (provided by applicant): CD47 has emerged as a novel therapeutic target in hematologic cancers. Leukemias expressing the highest levels of CD47 have the worst prognosis. Increased CD47 expression is thought to protect cancer cells from phagocytic clearance by sending a don't eat me… more

Single Cell chemical Imaging via nanoscale IR ablation - Mass Spectromety

Company: Anasys Instruments Corp Agency/Program/Year/Phase: HHS / STTR / 2013 / 1
Abstract: DESCRIPTION (provided by applicant): The goals of this project are twofold: a) to develop a new technique for nanoscale Mass spectrometry imaging based on AFM based tip enhanced IR ablation (nanoIR-MS). b) to apply this technique towards the application ofSingle cell imaging. Information on the… more

An intravaginal ring for real-time evaluation of adherence to topical vagina

Company: AURITEC PHARMACEUTICALS, INC. Agency/Program/Year/Phase: HHS / STTR / 2013 / 1
Abstract: DESCRIPTION (provided by applicant): The broad long-term of this project is to develop methods for evaluation of adherence to intravaginal microbicide therapy for the prevention of HIV transmission. Correct determination of adherence to preventative therapies in clinical trials is essential to… more

Remote focusing through spatial light modulation for multifocal multiphoton micro

Company: Boulder Nonlinear Systems, Inc. Agency/Program/Year/Phase: HHS / STTR / 2013 / 1
Abstract: DESCRIPTION (provided by applicant): Nonlinear optical microscopy techniques (such as two-photon florescence) are being used to acquire volumetric (i.e. three dimensional) images that probe several hundred microns into scattering tissue. These techniques are being combined with fast acquisition… more

Neurorestorative therapy of stroke with HUCBC in T2DM rats

Company: SANERON CCEL THERAPEUTICS, INC. Agency/Program/Year/Phase: HHS / STTR / 2013 / 1
Abstract: DESCRIPTION (provided by applicant): Diabetes mellitus (DM) leads to a 3-4 fold higher risk of experiencing ischemic stroke. In addition, DM stroke patients are more prone to develop more and earlier white matter (WM) high-intensity lesions than non DM stroke patients. Treatment of stroke with… more

Novel indication for myeloid progenitor use: Induction of tolerance

Company: CELLERANT THERAPEUTICS, INC. Agency/Program/Year/Phase: HHS / STTR / 2013 / 1
Abstract: DESCRIPTION (provided by applicant): State of the art techniques result in 10-year solid organ graft loss of up to 80% in cardiopulmonary organ transplantation, and re-transplantation is often not possible. Establishment of donor-specific immunological tolerance (DSIT), a condition in which a… more

Point of Care Device for Molecular Detection of HIV

Company: AC DIAGNOSTICS, INC. Agency/Program/Year/Phase: HHS / STTR / 2013 / 1
Abstract: DESCRIPTION (provided by applicant): According to recent estimates ~33 million people are living with HIV, with 96% residing in the developing world. While antiretroviral therapy is effective and increasingly available, the standard of care requires periodic monitoring of patients' viral load… more

Osteochondral tissue repair in an ovine model using a 3D woven poly (e-caprolacto

Company: CYTEX THERAPEUTICS INC. Agency/Program/Year/Phase: HHS / STTR / 2013 / 1
Abstract: DESCRIPTION (provided by applicant): Standard microfracture is a first-line, widely used and cost-effective surgical technique for repairing damaged articular cartilage, but, it is limited by decreased long-term efficacy and limited applicability in largerlesions. This leads to a burgeoning economic… more

Controlling mechanical signal transduction to treat osteoarthritis

Company: CYTEX THERAPEUTICS INC. Agency/Program/Year/Phase: HHS / STTR / 2013 / 1
Abstract: DESCRIPTION (provided by applicant): Controlling mechanical signal transduction to treat osteoarthritis Abstract The TRPV4 calcium (Ca++) permeable ion channel has been shown to be expressed and functional in chondrocytes, the cells responsible for the maintenance of cartilage in weight-bearing… more

A brief iPad-based screening measure for HIV-associated neurocognitive disorders

Company: DIGITAL ARTEFACTS, LLC Agency/Program/Year/Phase: HHS / STTR / 2013 / 1
Abstract: DESCRIPTION (provided by applicant): HIV-associated neurocognitive disorders (HAND) remain prevalent despite effective anti-retroviral treatments. Cognitive impairments in the current treatment era are often mild and not readily detectable because currentscreening measures (e.g., the HIV Dementia… more

The Development of TLR Antagonists for Therapy of Hepatic Fibrosis and Cirrhosis

Company: DYNAVAX TECHNOLOGIES CORPORATION Agency/Program/Year/Phase: HHS / STTR / 2013 / 1
Abstract: DESCRIPTION (provided by applicant): Hepatic fibrosis (HF) is a major health problem leading to cirrhosis and death. There is currently no pharmacological treatment for HF, and liver transplantation is unable to meet the needs of all patients afflicted with HF. We have shown that chronic liver… more

Orally Active Formulations of DHA Dimers for the Treatment of Infectious Diseases

Company: ELSOHLY LABORATORIES, INC. Agency/Program/Year/Phase: HHS / STTR / 2013 / 1
Abstract: DESCRIPTION (provided by applicant): The natural product artemisinin is a sesquiterpene endoperoxide with known anti-malarial activity against both chloroquine-sensitive and chloroquine-resistant strains of the parasite Plasmodium falciparum. In addition to its anti-malarial activity, artemisinin… more

A Thermo-responsive Biopharmaceutical to Enhance the Tear Production of Lacritin

Company: EYERX RESEARCH, INC. Agency/Program/Year/Phase: HHS / STTR / 2013 / 1
Abstract: Project Summary/Abstract Ocular pharmaceuticals predominantly use the topical route of administration, which involves a number of benefits and limitations when compared to systemic drug routes. A major limitation of the ocular topical route is the rapid loss of drug via tearing and nasolacrimal… more

Enhanced bioscavenger for medical countermeasures against organophosphorus agents

Company: Luna Innovations Incorporated Agency/Program/Year/Phase: HHS / STTR / 2013 / 1
Abstract: DESCRIPTION (provided by applicant): Counteracting the threat of intoxication by organophosphorus nerve agents (OP's) is an important mission for homeland security as well as for treating workers exposed to pesticides. OP's act on acetylcholinesterase to prevent synaptic inactivation,… more

Nanoparticle scavengers for medical countermeasures against mycotoxin

Company: Luna Innovations Incorporated Agency/Program/Year/Phase: HHS / STTR / 2013 / 1
Abstract: DESCRIPTION (provided by applicant): Mycotoxin is naturally occurring and is a toxic small molecule produced by fungi. These fungal toxins are representative of a large number of lipophilic agents that pose significant acute and chronic dangers to militarycombatants as potential warfare agents.… more

Live-Cell Fluorescence Lifetime FRET Assays for HTS

Company: FLUORESCENCE INNOVATIONS, INC. Agency/Program/Year/Phase: HHS / STTR / 2013 / 1
Abstract: DESCRIPTION (provided by applicant): This project will establish proof-of-concept for a powerful and versatile implementation of live-cell assays in a true high-throughput screening (HTS) format for small-molecule drug discovery. The technological basis isfluorescence lifetime (FLT) readout of FRET… more

Medical Images, HTML5, and Clinical Trial Remote Collaboration

Company: HEART IMAGING TECHNOLOGIES, LLC Agency/Program/Year/Phase: HHS / STTR / 2013 / 1
Abstract: DESCRIPTION (provided by applicant): Medical drugs and devices are regulated by the U.S. Food and Drug Administration (FDA) based on data from multicenter clinical trials. In 2010, U.S. spending on clinical trials was approximately 25 billion. Over the past decade the efficiency of clinical trials… more

Novel liver fibrosis test for early detection and classification

Company: IMMUNOTOPE, INC. Agency/Program/Year/Phase: HHS / STTR / 2013 / 1
Abstract: DESCRIPTION (provided by applicant): The overall goal of this application is to develop and validate a potential biomarker based assay to determine if it can be used as a noninvasive test to detect the stage of hepatic fibrosis and to predict fibrosis progression in HIV/HCV co-infected patients.… more

DC-SIGN Inhibitors for the Treatment of HIV Infection

Company: FOX CHASE CHEMICAL DIVERSITY CENTER, INC Agency/Program/Year/Phase: HHS / STTR / 2013 / 1
Abstract: DESCRIPTION (provided by applicant): DC-SIGN (dendritic cell specific ICAM-3-grabbing non-integrin), a membrane protein of C-type lectin family, is found in high levels on monocyte-derived DCs, some macrophages, and activated B cells. In vivo, DC-SIGN- positive cells were demonstrated in lymph nodes… more

New therapeutics for the treatment of Acinetobactor baumannii infections.

Company: FOX CHASE CHEMICAL DIVERSITY CENTER, INC Agency/Program/Year/Phase: HHS / STTR / 2013 / 1
Abstract: DESCRIPTION (provided by applicant): Acinetobacter are strictly aerobic, non-fermentative Gram-negative bacilli that are of major concern in human health, in particular the species Acinetobacter baumannii. They are responsible for clinically important infections that cause a wide variety of maladies… more

Evaluation of a new class of molecules for treating MRSA infective endocarditis

Company: AGILE SCIENCES, INC. Agency/Program/Year/Phase: HHS / STTR / 2013 / 1
Abstract: DESCRIPTION (provided by applicant): Patients with infective endocarditis (IE) have a poor prognosis with one third of the patients succumbing to the infection within the first year. Treatments for endocarditis involve antibiotic therapy and/or surgery that cost upwards of 100,000 per patient;… more